CINCINNATI and DURHAM, N.C., June 16, 2016 /PRNewswire/ — Schulman IRB, the industry-leading central IRB in customer service and technology, will be exhibiting at the 2016 Drug Information Association (DIA) Annual Meeting from June 27-29 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
Members of the Schulman Technology, Consulting, Study Management and Executive Leadership teams will be at Booth 1607 to discuss Schulman’s robust service offerings, including oncology review expertise and technology. In addition to exhibiting, Schulman will also host a private event at the One Liberty Observation Deck after Monday’s sessions. Attendees can get their exclusive invitation to the event by stopping by Schulman’s booth.
“DIA is a must-attend event for the clinical research community,” said Robann Cunningham, Vice President of Sales and Marketing at Schulman. “It’s an important opportunity for key thought leaders and innovators to share their views, knowledge and experiences with attendees across all disciplines. We look forward to meeting with everyone and contributing Schulman’s experience and expertise to the conversation.”
More than 7,000 professionals from industry, academia, regulatory and government agencies, health, patient and philanthropic organizations attend DIA annually. These individuals come from all disciplines involved in the discovery, development and life cycle management of health care products.
To learn more about the event, visit http://www.diaglobal.org/en/flagship/dia-2016/.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its joint venture partner Provision Research Compliance Services, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
SOURCE Schulman IRB